As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there's the potential ...

Heptares was also first to solve the glucagon-like peptide 1 (GLP-1) receptor structure 7, which could enable the next generation of today’s blockbuster anti-obesity drugs. In 2015, Heptares was ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are secreted from the same intestinal cells following meal ingestion. GLP-1 is now widely recognised to reduce blood glucose levels ...

In addition, NIPEP-TPP technology can be used to increase the oral-delivery efficacy of peptide therapeutics, such as parathyroid hormone (PTH) or glucagon-like peptide-1 (GLP-1) receptor agonists.

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Its structure comprises a sequence of amino ... may activate receptors involved in energy balance, such as the glucagon-like peptide-1 (GLP-1) receptor, glucagon receptor (GCGR), and glucose ...